Related Research Articles
The Wistar Institute is an independent, nonprofit research institution in biomedical science with special focuses in oncology, immunology, infectious disease and vaccine research. Located on Spruce Street in Philadelphia’s University City neighborhood, Wistar was founded in 1892 as a nonprofit institution to focus on biomedical research and training.
Axel Ullrich is a German cancer researcher and has been the director of the molecular biology department at the Max Planck Institute of Biochemistry in Martinsried, Germany since 1988. This department's research has primarily focused on signal transduction. Ullrich has received Hamdan Award for Medical Research Excellence, awarded by Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, Dubai, United Arab Emirates in 2008 and Ullrich and his team received the Wolf Prize in 2010.
Richard G. Pestell is an Australian American oncologist, endocrinologist and research scientist. Pestell was appointed an Officer of the Order of Australia for distinguished service to medicine and medical education in 2019 by Queen Elizabeth II. He was previously Executive Vice President of Thomas Jefferson University and Director of the Sidney Kimmel Cancer Center of Thomas Jefferson University. As a serial entrepreneur he founded six biotechnology companies developing cancer therapy and diagnostics. He is currently Distinguished Professor, Translational Medical Research, and the President of the Pennsylvania Cancer and Regenerative Medicine Research Center at the Baruch S. Blumberg Institute.
Survivin, also called baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5, is a protein that, in humans, is encoded by the BIRC5 gene.
Inhibitors of apoptosis are a group of proteins that mainly act on the intrinsic pathway that block programmed cell death, which can frequently lead to cancer or other effects for the cell if mutated or improperly regulated. Many of these inhibitors act to block caspases, a family of cysteine proteases that play an integral role in apoptosis. Some of these inhibitors include the Bcl-2 family, viral inhibitor crmA, and IAP's.
Sanford Burnham Prebys is a 501(c)(3) non-profit medical research institute focusing on basic and translational research, with major research programs in cancer, neurodegeneration, diabetes, infectious, inflammatory, and childhood diseases. The institute also specializes in stem cell research and drug discovery technologies.
Caspase-7, apoptosis-related cysteine peptidase, also known as CASP7, is a human protein encoded by the CASP7 gene. CASP7 orthologs have been identified in nearly all mammals for which complete genome data are available. Unique orthologs are also present in birds, lizards, lissamphibians, and teleosts.
Diablo homolog (DIABLO) is a mitochondrial protein that in humans is encoded by the DIABLO gene on chromosome 12. DIABLO is also referred to as second mitochondria-derived activator of caspases or SMAC. This protein binds inhibitor of apoptosis proteins (IAPs), thus freeing caspases to activate apoptosis. Due to its proapoptotic function, SMAC is implicated in a broad spectrum of tumors, and small molecule SMAC mimetics have been developed to enhance current cancer treatments.
Jay Tischfield is MacMillan Distinguished Professor and the Founding Chair of the Department of Genetics at Rutgers University. He is also Professor of Pediatrics and Psychiatry at Rutgers. He is currently Director of the Human Genetics Institute of New Jersey.
George C. Prendergast is an American biomedical scientist. His research has focused on cancer pathobiology and immunology. Since 2004, he has been the President and CEO of Lankenau Institute for Medical Research, a cancer-focused research center in the U.S. He is also the co-director of the Program in Cancer Cell Biology & Signaling at the Sidney Kimmel Cancer Center, Thomas Jefferson University.
Levon Michael Khachigian is an Australian medical research scientist notable for his work in vascular cell and molecular biology. He is a Professor in the Faculty of Medicine at the University of New South Wales.
Meenhard Herlyn is an American researcher who works as director of The Wistar Institute Melanoma Research in Philadelphia. Herlyn obtained his D.V.M. degree from the University of Veterinary Medicine, Hanover, in 1970. Following that, in 1976, he earned a D.Sc. in medical microbiology from the University of Munich. In 1976, he joined The Wistar Institute as an associate scientist, focusing on the emerging field of monoclonal antibodies—a groundbreaking technology that now underlies a significant portion of targeted therapeutics. Transitioning to the role of assistant professor in 1981, Herlyn established a renowned laboratory dedicated to studying melanoma biology, which remains highly regarded in the field to this day. His primary research focus is the underlying biology behind melanoma, the most aggressive form of skin cancer. Over the course of his career, he has been responsible for the use of three-dimensional artificial skin cultures to study tumor and normal cells, a clearer understanding of stem cells and how they relate to cancer, and signaling pathways related to cancer. The Wistar Melanoma (WM) cell lines that Herlyn has used and helped discover in his laboratory are responsible for a better understanding of the major steps of tumor progression in human cases of melanoma.
Russel E. Kaufman is an American researcher who is president emeritus of The Wistar Institute in Philadelphia. In addition to his administrative role at Wistar, Kaufman maintains a research program that focuses on the genetics behind various types of blood diseases and cancer. During his time in research, some of Kaufman's discoveries include the characterization of the β-globin genes and the discovery of the CD7 ligand, K12. Additionally, he has focused on the regulation of genes expressed in hematopoietic stem cells and their progenitors.
Paul M. Lieberman is an American biomedical researcher and chairperson of the Gene Expression and Regulation Program at the Ellen and Ronald Caplan Cancer Center at The Wistar Institute in Philadelphia. He is also the Hilary Koprowski, M.D., endowed professor, the McNeil professor of Molecular Medicine and Translational Research, and the founding director for the Center for Chemical Biology and Translational Medicine at The Wistar Institute. Lieberman's research focuses on how viruses cause cancer and autoimmune disease, particularly the Epstein–Barr virus.
György Kéri was a Hungarian biochemist, professor and Doctor of Biological Sciences (D.Sc.). His major field of research was signal transduction therapy and he participated in the development of novel drug discovery technologies and drug candidates that entered the clinical development process.
Don W. Cleveland is an American cancer biologist and neurobiologist.
Tapas Kumar Kundu is an Indian molecular biologist, academician and at present the Director of Central Drug Research Institute, a prestigious research institute of Council of Scientific and Industrial Research at Lucknow. He is the head of the Transcription and Disease Laboratory of Jawaharlal Nehru Centre for Advanced Scientific Research. He is known for his studies on the regulation of Gene expression and his contributions in cancer diagnostics and the development of new drug candidates for cancer and AIDS therapeutics. He is an elected fellow of the Indian Academy of Sciences, Indian National Science Academy and the National Academy of Sciences, India and a J. C. Bose National Fellow of the Department of Science and Technology. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, in 2005, for his contributions to biological sciences. He is also a recipient of the National Bioscience Award for Career Development of the Department of Biotechnology.
Michael Green was an American molecular biologist and cell biologist at the University of Massachusetts Medical School, where he was the chair of the Department of Molecular, Cell and Cancer Biology, director of the UMass Cancer Center, and a Howard Hughes Medical Institute investigator. Green was a member of the National Academy of Sciences and the National Academy of Medicine.
Chi Van Dang is a hematological oncologist and researcher, currently serving as the Scientific Director of Ludwig Institute for Cancer Research. He is known for his research on genetics, the MYC gene and the cellular energy metabolism of cancer.
Juan Carlos Lacal Sanjuán is a Spanish biologist, biochemist, inventor and academic. He is a professor of Research at the Sols-Morreale Biomedical Research Institute, which is run by the Spanish National Research Council (CSIC) and the Autonomous University of Madrid (UAM).
References
- 1 2 "Dario C. Altieri: Chief Executive Officer of Wistar Institute". The University of Pennsylvania . Retrieved 2 March 2015.
- ↑ "Cancer Biologist Dario Altieri to Lead the Wistar Institute Cancer Center". The Wistar Institute. Retrieved 11 February 2014.
- 1 2 "Biography Dario C. Altieri, MD.; Association of American Cancer Institutes".
- ↑ "Gene "survivin" inhibits cell death" (PDF). Yale Cancer Center. Retrieved 2023-03-15.
- ↑ "Dario C. Altieri, M.D." The Wistar Institute . Retrieved 28 January 2014.
- ↑ "Thrivin' (not just survivin') in Philadelphia". The Journal of Clinical Investigation . Retrieved 28 January 2014.
- ↑ "Emerging Research Fronts - 2009". ScienceWatch. Retrieved 11 February 2014.
- ↑ "Wistar Receives $1.5 Million Department of Defense Grant To Ready Potential Prostate Drug For Clinical Use". The Wistar Institute. Archived from the original on 22 February 2014. Retrieved 28 January 2014.
- ↑ "Combinatorial Drugs Target Cancer Cell Mitochonndria". biotechdaily.com. Retrieved 11 February 2014.
- ↑ "Cancer Biologist Dario Altieri to Lead the Wistar Institute Cancer Center". The Wistar Institute . Retrieved 28 January 2014.